Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Digital platform aims to Fine-Tune heart failure drugs after hospital stay

NCT ID NCT07352891

Disease control Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a digital remote-management platform can help doctors better adjust heart failure medications after patients leave the hospital. About 252 adults with heart failure and reduced pumping function will use the platform to report symptoms and vital signs, with an algorithm suggesting medication changes. The goal is to see if this approach leads to more optimized drug therapy compared to usual care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 252 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged ≥18 years. 2. Hospitalised at a secondary or tertiary hospital with established heart failure care capacity. 3. Diagnosed with HFrEF within the past 3 months according to the 2022 ACC/AHA/HFSA guideline diagnostic pathway, including: LVEF ≤40% by echocardiography; typical heart-failure symptoms and/or signs; and exclusion of non-HF causes of symptoms. 4. Not optimized on guideline-directed medical therapy (GDMT) at enrollment, defined as at least two of the following four foundational drug classes not initiated or administered at \<50% target dose. 5. Written informed consent provided. Exclusion Criteria: 1. Absolute contraindication to heart failure pharmacotherapy. 2. History of heart transplantation or currently on a transplant waiting list. 3. Receiving or planning implantation of a left ventricular assist device. 4. Pregnant or breastfeeding women. 5. Organ transplantation within the past 12 months. 6. Unable to use the remote management platform as required (e.g., cognitive impairment or lack of caregiver support). 7. Unable to perform blood pressure or body-weight monitoring (e.g., severe limb disability). 8. Unable to express willingness or comply with follow-up requirements (e.g., unable to use internet-enabled devices). 9. Any other condition judged by the investigator to make the patient unsuitable for participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with reduced ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure with reduced ejection fraction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Anzhen Hospital, Capital Medical University, Beijing, China

    RECRUITING

    Beijing, China

  • Beijing Tongren Hospital, Capital Medical University, Beijing, China

    RECRUITING

    Beijing, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    NOT_YET_RECRUITING

    Shanghai, China

  • The First Affiliated Hospital of Dalian Medical University, Dalian, China

    RECRUITING

    Dalian, China

  • The First Hospital of Jilin University, Changchun, China

    RECRUITING

    Jilin City, China

  • The Second Affiliated Hospital of Nanchang University, Nanchang, China

    NOT_YET_RECRUITING

    Nanchang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.